Q-omics provides the consensus-scored NANOGP9 profile across patient tissues and cancer cell-line models. NANOGP9 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, NANOGP9 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, NANOGP9 RNA expression shows 6,510 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, BRCA, and STAD as cancer lineages where NANOGP9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NANOGP9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NANOGP9 survival associations across molecular data types. NANOGP9 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NANOGP9 RNA expression–survival associations across cancer types. High NANOGP9 expression shows unfavorable associations in KICH, LUSC, THCA and LUAD, but favorable associations in LAML and PAAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for NANOGP9 RNA expression.
This table summarizes NANOGP9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for NANOGP9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NANOGP9 shows lower tumor expression in BRCA, COAD and KIRC. The BRCA box plot shows higher NANOGP9 RNA expression in normal versus tumor tissue (log2 FC = −0.116, t-test p = .029).
This table shows molecular features associated with NANOGP9 in patient tissues and cancer cell lines. In patient samples, NANOGP9 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
